英諾激光(301021.SZ):在超精密加工領域,高功率薄片超快激光器可實現高效加工,有效減少飛屑毛刺、提升生產效率
格隆匯7月29日丨英諾激光(301021.SZ)在投資者互動平台表示,在超精密加工領域,高功率薄片超快激光器可實現高效加工,有效減少飛屑毛刺、提升生產效率;在半導體領域,大能量、高重頻超快激光是支撐EUV光源預脈衝的核心技術;在前沿科學領域,薄片激光技術是實現高平均功率阿秒驅動脈衝的有效手段,為阿秒技術走向商用提供了有效路徑;在新型顯示等其他高端加工場景,高功率、大脈衝能量的紫外、深紫外薄片激光器將以更好的穩定性和更優的成本替代目前尚需進口的準分子激光器,可見薄片激光器在諸多的高端和尖端領域有着廣闊的應用前景,將支撐這些領域的發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.